Oral Solid Dosage Contract Manufacturing Market by Product Type (Powder, Granule, Tablets, and Capsules), Mechanism (Controlled-release, Delayed-release, and Immediate-release), End-user (Large-Size Companies and Medium- & Small Size-Companies), and Region (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2023 – 2031
Oral Solid Dosage Contract Manufacturing Market Outlook 2031
The global Oral Solid Dosage Contract Manufacturing market size was USD 31.1 Bn in 2022 and is likely to reach USD 50 Bn by 2031, expanding at a CAGR of 5.6% during 2023–2031. The market growth is attributed to the rising aging population and growing advancements in drug development.
Rising demand for biosimilars and specialized formulations in oral solid dosage forms is anticipated to significantly boost the market. Increasing population and healthcare needs create high healthcare demand leading to a large supply of pharmaceuticals.
Oral solid dosage (OSD) contract manufacturing refers to the outsourcing of the production of pharmaceutical products that are in a solid form intended for oral administration. This includes tablets, capsules, powders, and other similar forms.
The market report finds that the COVID-19 pandemic affected the oral solid dosage contract manufacturing market. The pandemic led to disruptions in global supply chains due to lockdowns, travel restrictions, and closures of manufacturing facilities. This affected the sourcing of raw materials, packaging materials, and other essential components required for OSD production.
The pandemic surged the demand for specific medications such as those used to treat COVID-19 symptoms and related conditions. This increased the production of oral solid dosage forms, putting pressure on contract manufacturers to extend production quickly.
Oral Solid Dosage Contract Manufacturing Market Dynamics
Major Drivers
Increasing demand for pharmaceuticals drives the oral solid dosage contract manufacturing market. The global population is increasing, which leads to a rising geriatric population, they have a high need for pharmaceutical interventions to manage chronic health conditions. Rising incidences of chronic diseases such as cardiovascular diseases, diabetes, and respiratory disorders often require long-term medication, which increases the demand for oral solid dosage forms. For instance,
-
As per the recent data published, the total global population is expected to reach USD 8 billion in 2023.
Existing Restraints
Regulatory compliance and quality assurance hampers the market. The pharmaceutical industry is highly regulated and contract manufacturers need to follow a range of standards including good manufacturing practices (GMP) is costly. They require substantial investments in training, equipment, and documentation, which increases operational costs for contract manufacturers.
Emerging Opportunities
Growing adoption of advanced manufacturing technologies (AMTs) creates lucrative opportunities for the market. Adoption of advanced manufacturing technologies such as continuous manufacturing and 3D printing can enhance efficiency and flexibility in OSD production. AMTs often integrate advanced quality control systems including real-time monitoring and analytics. This leads to high product quality, which complies with regulatory standards by improving overall customer satisfaction.
Scope of the Oral Solid Dosage Contract Manufacturing Market Report
The market report includes an assessment of the market trends, segments, and regional markets. Overview and dynamics have also been included in the report.
Attributes |
Details |
Report Title |
Oral Solid Dosage Contract Manufacturing Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast |
Base Year |
2022 |
Historic Data |
2016–2021 |
Forecast Period |
2023–2031 |
Segmentation |
Product Type (Powder, Granule, Tablets, and Capsules), Mechanism (Controlled-release, Delayed-release, and Immediate-release), and End-user (Large-Size Companies and Medium- & Small-Size Companies) |
Regional Scope |
Asia Pacific, North America, Latin America, Europe, and Middle East & Africa |
Report Coverage |
Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, Market Trends, and Revenue Forecast |
Key Players Covered in the Report |
Aenova Holding GmbH; AbbVie Inc.; Boehringer Ingelheim International GmbH; CordenPharma International; Catalent, Inc; Jubilant Pharma Limited; Lonza; NextPharma Technologies; Piramal Pharma Solutions; Recipharm AB; Siegfried Holding AG; and Thermo Fisher Scientific Inc. |
Market Segment Insights
Product Type Segment Analysis
Based on product type, the oral solid dosage contract manufacturing market is divided into powder, granule, tablets, and capsules. The tablet segment holds segment is expected to hold a dominant share of the market during the projection period, due to it providing ease of administration and offering diverse formulations.
Tablets are one of the highly preferred oral dosage forms among patients. They are easy to swallow, convenient to carry, and have a longer shelf life as compared to other dosage forms. Tablets offer flexibility in formulation design. They can be formulated in various ways including immediate-release, extended-release, and controlled-release formulations. This versatility allows pharmaceutical manufacturers to cater to a wide range of patient needs and therapeutic requirements.
The capsules segment is expected to expand at a significant pace in the coming years, as it provides improved bioavailability and reduced disintegration time. Capsules often provide superior bioavailability for certain drugs compared to tablets, as they can contain a wide range of formulations including powders, granules, or even liquids. Capsules are disintegrated more quickly in the digestive system as compared to tablets. This leads to faster absorption of the active ingredient, which is beneficial for drugs that require rapid onset of action.
Mechanism Segment Analysis
On the basis of mechanism, the global market is segregated into controlled-release, delayed-release, and immediate-release. The controlled-released segment is projected to register a high CAGR during the forecast period due to increasing demand for long-acting formulation and the fluctuation in plasma levels.
Growing demand for medications that offer prolonged therapeutic effects, which allows for less frequent dosing. Controlled-release formulations fulfill this need by releasing the active ingredient gradually over an extended period, resulting in reduced dosing frequency. Controlled-release mechanisms help maintain a consistent concentration of the active ingredient in the body. This minimizes fluctuations in drug plasma levels, which reduces side-effects and eases the therapeutic experience for patients.
End-user Segment Analysis
On the basis of end-user, the oral solid dosage contract manufacturing market is segmented into large-size companies and medium- & small-size companies. The large-size companies segment is anticipated to register a robust growth rate during the forecast period due to economies of scale and it provides a diverse product portfolio.
Large pharmaceutical companies often have the financial resources to invest in advanced manufacturing facilities and technologies. This enables them to achieve economies of scale by producing OSD products in high volumes, which leads to cost savings. Large-size companies typically have a diverse portfolio of products across various therapeutic areas. This necessitates a wide range of OSD formulations that can be efficiently produced by specialized contract manufacturers.
The medium- & small-size companies segment is expected to expand at a significant growth rate in the coming years, due to outsourcing for cost-efficiency and focus on core competencies. Medium- and small-size companies often have limited resources and do not have the capital to invest in their own manufacturing facilities. They outsource OSD production and reduce capital expenditure, operational costs, and overhead expenses associated with in-house manufacturing.
They prioritize activities such as R&D and marketing and choose to partner with specialized contract manufacturers for the production of OSD products. This allows them to allocate resources strategically and focus on their areas of expertise.
Regional Outlook
In terms of region, the global oral solid dosage contract manufacturing market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. Asia Pacific is expected to dominate the market during the projection period due to region provides a cost-effective solution and strong manufacturing infrastructure.
Emerging economies within Asia Pacific, particularly India and China, are known for offering cost-effective solutions in OSD contract manufacturing. This cost advantage is a significant driver for pharmaceutical companies looking to optimize their production expenses. Asia Pacific has a well-established and robust manufacturing infrastructure, with advanced facilities equipped to handle OSD production on a large scale. This infrastructure supports efficient and streamlined manufacturing processes. For instance,
-
In June 2020, Piramal Enterprises Ltd. acquired G&W Laboratories Inc.’s oral solid dosage drug manufacturing facility in Sellersville, Pennsylvania, in the US. This acquisition significantly increased Piramal Pharma Solutions’ (PPS) presence in North America by enriching its offerings with enhanced capabilities in producing oral solid dosage forms, encompassing tablets and capsules.
The market in North America is projected to grow rapidly during the forecast period, owing to the advanced healthcare infrastructure and stringent regulatory standards. North America boasts a highly developed and sophisticated healthcare infrastructure. This includes advanced manufacturing facilities, research institutions, and regulatory agencies, providing a favorable environment for OSD contract manufacturing. North America has a strict regulatory environment that ensures products manufactured in the region meet rigorous quality and safety requirements.
2. Assumptions and Acronyms Used
3. Research Methodology
4. Oral Solid Dosage Contract Manufacturing Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Oral Solid Dosage Contract Manufacturing Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Oral Solid Dosage Contract Manufacturing Market - Supply Chain
4.5. Global Oral Solid Dosage Contract Manufacturing Market Forecast
4.5.1. Oral Solid Dosage Contract Manufacturing Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Oral Solid Dosage Contract Manufacturing Market Size (000’ Units) and Y-o-Y Growth
4.5.3. Oral Solid Dosage Contract Manufacturing Market Absolute $ Opportunity
5. Global Oral Solid Dosage Contract Manufacturing Market Analysis and Forecast by End Users
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by End Users
5.2.2. Y-o-Y Growth Projections by End Users
5.3. Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by End Users
5.3.1. Large-Size Companies
5.3.2. Medium- & Small-Size Companies
5.4. Absolute $ Opportunity Assessment by End Users
5.5. Market Attractiveness/Growth Potential Analysis by End Users
6. Global Oral Solid Dosage Contract Manufacturing Market Analysis and Forecast by Region
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Region
6.2.2. Y-o-Y Growth Projections by Region
6.3. Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by Region
6.3.1. North America
6.3.2. Latin America
6.3.3. Europe
6.3.4. Asia Pacific
6.3.5. Middle East and Africa (MEA)
6.4. Absolute $ Opportunity Assessment by Region
6.5. Market Attractiveness/Growth Potential Analysis by Region
6.6. Global Oral Solid Dosage Contract Manufacturing Demand Share Forecast, 2019-2026
7. North America Oral Solid Dosage Contract Manufacturing Market Analysis and Forecast
7.1. Introduction
7.1.1. Basis Point Share (BPS) Analysis by Country
7.1.2. Y-o-Y Growth Projections by Country
7.2. North America Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by Country
7.2.1. U.S.
7.2.2. Canada
7.3. Absolute $ Opportunity Assessment by Country
7.4. North America Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by End Users
7.4.1. Large-Size Companies
7.4.2. Medium- & Small-Size Companies
7.5. Basis Point Share (BPS) Analysis by End Users
7.6. Y-o-Y Growth Projections by End Users
7.7. Market Attractiveness/Growth Potential Analysis
7.7.1. By Country
7.7.2. By Product Type
7.7.3. By Application
7.8. North America Oral Solid Dosage Contract Manufacturing Demand Share Forecast, 2019-2026
8. Latin America Oral Solid Dosage Contract Manufacturing Market Analysis and Forecast
8.1. Introduction
8.1.1. Basis Point Share (BPS) Analysis by Country
8.1.2. Y-o-Y Growth Projections by Country
8.1.3. Latin America Average Pricing Analysis
8.2. Latin America Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by Country
8.2.1. Brazil
8.2.2. Mexico
8.2.3. Rest of Latin America
8.3. Absolute $ Opportunity Assessment by Country
8.4. Latin America Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by End Users
8.4.1. Large-Size Companies
8.4.2. Medium- & Small-Size Companies
8.5. Basis Point Share (BPS) Analysis by End Users
8.6. Y-o-Y Growth Projections by End Users
8.7. Market Attractiveness/Growth Potential Analysis
8.7.1. By Country
8.7.2. By Product Type
8.7.3. By Application
8.8. Latin America Oral Solid Dosage Contract Manufacturing Demand Share Forecast, 2019-2026
9. Europe Oral Solid Dosage Contract Manufacturing Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.1.3. Europe Average Pricing Analysis
9.2. Europe Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by Country
9.2.1. Germany
9.2.2. France
9.2.3. Italy
9.2.4. U.K.
9.2.5. Spain
9.2.6. Russia
9.2.7. Rest of Europe
9.3. Absolute $ Opportunity Assessment by Country
9.4. Europe Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by End Users
9.4.1. Large-Size Companies
9.4.2. Medium- & Small-Size Companies
9.5. Basis Point Share (BPS) Analysis by End Users
9.6. Y-o-Y Growth Projections by End Users
9.7. Market Attractiveness/Growth Potential Analysis
9.7.1. By Country
9.7.2. By Product Type
9.7.3. By Application
9.8. Europe Oral Solid Dosage Contract Manufacturing Demand Share Forecast, 2019-2026
10. Asia Pacific Oral Solid Dosage Contract Manufacturing Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Asia Pacific Average Pricing Analysis
10.2. Asia Pacific Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by Country
10.2.1. China
10.2.2. Japan
10.2.3. South Korea
10.2.4. India
10.2.5. Australia
10.2.6. Rest of Asia Pacific (APAC)
10.3. Absolute $ Opportunity Assessment by Country
10.4. Asia Pacific Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by End Users
10.4.1. Large-Size Companies
10.4.2. Medium- & Small-Size Companies
10.5. Basis Point Share (BPS) Analysis by End Users
10.6. Y-o-Y Growth Projections by End Users
10.7. Market Attractiveness/Growth Potential Analysis
10.7.1. By Country
10.7.2. By Product Type
10.7.3. By Application
10.8. Asia Pacific Oral Solid Dosage Contract Manufacturing Demand Share Forecast, 2019-2026
11. Middle East & Africa Oral Solid Dosage Contract Manufacturing Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Middle East & Africa Average Pricing Analysis
11.2. Middle East & Africa Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by Country
11.2.1. Saudi Arabia
11.2.2. South Africa
11.2.3. UAE
11.2.4. Rest of Middle East & Africa (MEA)
11.3. Absolute $ Opportunity Assessment by Country
11.4. Middle East & Africa Oral Solid Dosage Contract Manufacturing Market Size and Volume Forecast by End Users
11.4.1. Large-Size Companies
11.4.2. Medium- & Small-Size Companies
11.5. Basis Point Share (BPS) Analysis by End Users
11.6. Y-o-Y Growth Projections by End Users
11.7. Market Attractiveness/Growth Potential Analysis
11.7.1. By Country
11.7.2. By Product Type
11.7.3. By Application
11.8. Middle East & Africa Oral Solid Dosage Contract Manufacturing Demand Share Forecast, 2019-2026
12. Competition Landscape
12.1. Global Oral Solid Dosage Contract Manufacturing Market: Market Share Analysis
12.2. Oral Solid Dosage Contract Manufacturing Distributors and Customers
12.3. Oral Solid Dosage Contract Manufacturing Market: Competitive Dashboard
12.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
12.4.1. Aenova Holding GmbH
12.4.2. AbbVie Inc.
12.4.3. Boehringer Ingelheim International GmbH
12.4.4. CordenPharma International
12.4.5. Catalent, Inc
12.4.6. Jubilant Pharma Limited
12.4.7. Lonza
12.4.8. NextPharma Technologies
12.4.9. Piramal Pharma Solutions
12.4.10. Recipharm AB
12.4.11. Siegfried Holding AG
12.4.12. Thermo Fisher Scientific Inc.